IL6 and COVID-19: Using an in vitro model of human hippocampal progenitor cells, we have already demonstrated that treatment with high concentrations of IL6, similar to those found in peripheral blood of COVID-19 patients (~50-500 pg/ml) [12, 21], can reduce neurogenesis and increase apoptosis [22, 23].